C12Y 101/01062
17beta-estradiol 17-dehydrogenase
Official title: 17Beta-estradiol 17-dehydrogenase (1.1.1.62)
C12Y101/01062 (17beta-estradiol 17-dehydrogenase) appears on 7 US grants and 15 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 15
- Assignees
- 8
- Inventors
- 54
- Latest grant
- 19 Dec 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 2 | 2 |
| 2024 | 0 | 5 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- HSD17B13 variants and uses thereof19 Dec 2023US 11,845,963 B2Regeneron Pharmaceuticals, Inc.
- HSD17B13 variants and uses thereof12 Sep 2023US 11,753,628 B2Regeneron Pharmaceuticals, Inc.
- HSD17B13 variants and uses thereof1 Nov 2022US 11,485,958 B2Regeneron Pharmaceuticals, Inc.
- HSD17B13 variants and uses thereof29 Sep 2020US 10,787,647 B2Regeneron Pharmaceuticals, Inc.
- Process for the preparation of testosterone26 Nov 2013US 8,592,178 B2F.I.S. - Fabbrica Italiana Sintetici S.p. A.
- 17beta-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof2 Oct 2025US 2025/0304967 A1Alnylam Pharmaceuticals, Inc.
- Hsd17b13-related double stranded oligonucleotide compositions and methods relating thereto21 Nov 2024US 2024/0384273 A1Wave Life Sciences Ltd.
- Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof24 Oct 2024US 2024/0352464 A1
- Sirna targeting 17beta-hydroxysteroid dehydrogenase type 13 and sirna conjugate11 Jul 2024US 2024/0229037 A1Tuojie Biotech (Shanghai) Co., Ltd.
- Hsd17b13 variants and uses thereof2 May 2024US 2024/0141305 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Intracellular amyloid-beta peptide binding (ERAB) polypeptide16US 6,268,479 B1The Trustees of Columbia University in the City of New York · 2001
- HSD17B13 variants and uses thereof10US 10,787,647 B2Regeneron Pharmaceuticals, Inc. · 2020
- Intracellular amyloid-beta binding (ERAB) polypeptide-related assays5US 6,994,974 B1The Trustees of Columbia University in the City of New York · 2006
- HSD17B13 variants and uses thereof1US 11,485,958 B2Regeneron Pharmaceuticals, Inc. · 2022
- HSD17B13 variants and uses thereof1US 11,753,628 B2Regeneron Pharmaceuticals, Inc. · 2023